The Cell and Gene Therapy Catapult (CGT Catapult) is setting up offices and laboratories in Edinburgh, Scotland. With this expansion, CGT Catapult aims to provide additional, regionally focused support to the cell and gene therapy sector to accelerate product development, clinical trials and adoption.
CGT Catapult Edinburgh is a collaboration with the University of Edinburgh and will be located at the Institute for Regeneration and Repair in the Edinburgh BioQuarter. CGT Catapult Edinburgh will provide advice to enable technology development, good manufacturing practices (GMP) translation and clinical trial acceleration to drive company formation and spin-out for the sector in Scotland and the North of England.
The centre will be led by Dr Jacqueline Barry, Chief Clinical Officer at CGT Catapult, and will work with academic and pharmaceutical services in central Scotland to drive advanced therapy medicinal product (ATMP) cluster formation and build the UK’s prominence in ATMP development and supply.
Matthew Durdy, Chief Executive Officer, CGT Catapult, said: “Edinburgh has developed an excellent academic base and the Institute for Regeneration and Repair is projected to have the largest accumulation of stem cell scientists in Europe, with nearly 500 currently located there. We look forward to building on this local expertise and growing the existing infrastructure to create a cluster for the cell and gene therapy industry in Scotland and the North of England. This will help bring these potentially life changing therapies to patients and help create economic opportunity in region.”
Image credit: K Mitch Hodge
